Pembrolizumab for the treatment of renal cell carcinoma.

Di Bona, Carlo; Stühler, Viktoria; Rausch, Steffen; Stenzl, Arnulf; Bedke, Jens

Di Bona, Carlo; Stühler, Viktoria; Rausch, Steffen; Stenzl, Arnulf; Bedke, Jens.

Di Bona C; Department of Urology, University of Tübingen, Tuebingen, Germany.
Stühler V; Department of Urology, University of Tübingen, Tuebingen, Germany.
Rausch S; Department of Urology, University of Tübingen, Tuebingen, Germany.
Stenzl A; Department of Urology, University of Tübingen, Tuebingen, Germany.
Bedke J; Department of Urology, University of Tübingen, Tuebingen, Germany.

Expert Opin Biol Ther ; 21(9): 1157-1164, 2021 09.

Article en En | MEDLINE | ID: mdl-34042015

Asunto(s)

Carcinoma de Células Renales; Neoplasias Renales; Anticuerpos Monoclonales Humanizados/uso terapéutico; Carcinoma de Células Renales/tratamiento farmacológico; Humanos; Neoplasias Renales/tratamiento farmacológico; Calidad de Vida

Palabras clave

Axitinib; genitourinary tumors; immune checkpoint inhibitor; pd-1; pd-l1; pembrolizumab; renal cell carcinoma

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google